Bain Capital Nears Deal for Majority Stake in Volkswagen Marine Engine Unit Everllence 
U.S. Dollar Reaches One-Year High as Tech Sell-Off and Fed Rate Hike Expectations Support Demand 
Alphabet Replaces Verizon in Dow Jones Industrial Average 
Gold Falls Below $4,000 as Strong Dollar and Fed Rate Hike Expectations Weigh on Prices 
RFK Jr. Orders Extended Hantavirus Quarantine for Cruise Passenger 
NASA Artemis II: First Crewed Moon Mission Since Apollo Takes Four Astronauts on 10-Day Lunar Journey 
NASA and SpaceX Target Crew-11 Undocking From ISS Amid Medical Concern 
FDA Pilot Program Eases Rules for Nicotine Pouch Makers 
Trump Administration Releases New UFO Files and Apollo Mission Records 
CDC Monitors U.S. Travelers After Hantavirus Outbreak on Luxury Cruise Ship 
White House Seeks $87.6 Billion Emergency Funding for Iran War, Farmers, and Ebola Response 
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment 
Neuralink Plans High-Volume Brain Implant Production and Fully Automated Surgery by 2026 
Anthropic AI Model Uncovers Vulnerabilities in Classified U.S. Government Systems During Security Test 
SpaceX Eyes Starlink Mobile Phone Service to Challenge Verizon, AT&T, and T-Mobile 
Bayer Wins Major U.S. Supreme Court Roundup Lawsuit, Shares Surge 
South Korea’s Celltrion Inc. will jointly develop and work on the market release with Abpro Corp. of the US on a breast cancer treatment candidate ABP 10
Under the deal, Celltrion will receive US$10 million in milestone payments after successfully passing key stages of the development and approval cycle.
Celltrion, an Incheon-based biopharmaceutical company, will also be eligible to collect $1.75 billion from Abpro after ABP 102 generates sales following its market debut. Additionally, it has secured the rights for the candidate's international sales.
The Massachusetts-based Abpro is developing eight other cancer treatment candidates.
ABP 102 is a dual antibody treatment used to treat breast cancer that is HER2-positive.
